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BACKGROUND: It has been suggested that cancer registries in England are too dependent on processing of information from death
certificates, and consequently that cancer survival statistics reported for England are systematically biased and too low.
METHODS: We have linked routine cancer registration records for colorectal, lung, and breast cancer patients with information from
the Hospital Episode Statistics (HES) database for the period 2001–2007. Based on record linkage with the HES database, records
missing in the cancer register were identified, and dates of diagnosis were revised. The effects of those revisions on the estimated
survival time and proportion of patients surviving for 1 year or more were studied. Cases that were absent in the cancer register and
present in the HES data with a relevant diagnosis code and a relevant surgery code were used to estimate (a) the completeness of
the cancer register. Differences in survival times calculated from the two data sources were used to estimate (b) the possible extent
of error in the recorded survival time in the cancer register. Finally, we combined (a) and (b) to estimate (c) the resulting differences
in 1-year cumulative survival estimates.
RESULTS: Completeness of case ascertainment in English cancer registries is high, around 98–99%. Using HES data added 1.9%, 0.4%
and 2.0% to the number of colorectal, lung, and breast cancer registrations, respectively. Around 5–6% of rapidly fatal cancer
registrations had survival time extended by more than a month, and almost 3% of rapidly fatal breast cancer records were extended
by more than a year. The resulting impact on estimates of 1-year survival was small, amounting to 1.0, 0.8, and 0.4 percentage points
for colorectal, lung, and breast cancer, respectively.
INTERPRETATION: English cancer registration data cannot be dismissed as unfit for the purpose of cancer survival analysis. However,
investigators should retain a critical attitude to data quality and sources of error in international cancer survival studies.
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It has been suggested that cancer registries in England are too
dependent on the processing of information from death certificates
(Bullard et al, 2000; Robinson et al, 2007; Beral and Peto, 2010;
Møller et al, 2010). This could have several adverse effects: (a) case
ascertainment would be incomplete, particularly for non-fatal
cases; (b) survival time would be too short, because hospital
activity related to recurrent disease or end-of-life care would
sometimes be recorded as the first known event and hence provide
the date of diagnosis. A further consequence of these errors would
be that (c) reported cancer survival statistics for England would be
estimated with a systematic bias and be too low.
Cancer registries in England have recently linked routine cancer
registration records with information from the Hospital Episode
Statistics (HES) database (http://www.hesonline.nhs.uk). The HES
database contains details of all in-patient and day-case admissions
to National Health Service (NHS) hospitals in England.
The linked data set provides a new opportunity to evaluate the
magnitude of errors (a), (b), and (c), defined above. Based on
record linkage with the HES database, records missing in the
cancer register were identified, and dates of diagnosis were revised.
The effects of those revisions on the estimated survival time and
proportion of patients surviving for 1 year or more were studied.
Cases that were absent in the cancer register and present in the
HES data with a relevant diagnosis code and a relevant surgery
code were used to estimate (a) the completeness of the cancer
register. Differences in survival times calculated from the two data
sources were used to estimate (b) the possible extent of error in the
recorded survival time in the cancer register. Finally, we combined
(a) and (b) to estimate (c) the resulting differences in 1-year
cumulative survival estimates.
The analyses presented here were executed at the Thames
Cancer Registry on behalf of cancer registries in England, in order
to address the comments in a recent editorial by Beral and
Peto (2010). The principal analysis and the form of reporting of
findings were specified before we had any knowledge of the results
of the investigation.
MATERIALS AND METHODS
We identified all cancer records in the HES-only side of the linked
data set that in 2001–2007 had activity relating to colorectal cancer
(ICD10 C18–C21), lung cancer (C33–C34), or breast cancer (C50),
and that had a surgery code indicating a relevant, non-diagnostic
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cases identified by the record linkage, that are not present in the
cancer register but present in the HES data with a relevant
diagnosis code and a relevant surgery code. These cases would not
be included in routine cancer survival analysis, and they represent
good-prognosis cases that may have been missed in the primary
case ascertainment in the cancer registries, and not subsequently
identified through routine record linkage with death certificates.
The three cancer diagnosis groups were selected to represent the
spectrum of fatality among different, common types of cancer.
The HES-only records were considered as an indication of the
possible magnitude of under-ascertainment of non-fatal cancer
cases in the cancer registries.
We considered only surgically treated cases because the
combination of diagnosis code and resection code in the HES
record gives a high degree of certainty that the record represents
a true record of cancer. The HES-only records without an
indication of cancer treatment would not be considered as
sufficient evidence to create a cancer registration, and would need
to be verified against other clinical records. The large majority of
such HES-only records are known to relate to cases where cancer
might have been suspected but it was not subsequently confirmed
(Brewster et al, 1997).
To give a measure of incompleteness, we compared the number
of HES-only records (with surgical treatment) against the number
of regular cancer registration records in the linked data set, and
Table 1 Completeness of case ascertainment in cancer registries in England, 2001–2007, evaluated with HES records containing both a relevant diagnosis
code and a relevant code for non-diagnostic surgery
Colorectal cancer Lung cancer Breast cancer
HESO REPO H/R (%) HESO REPO H/R (%) HESO REPO H/R (%)
Total 4027 206794 1.9 802 219483 0.4 4921 251201 2.0
Sex
Male 2050 111787 1.8 458 128881 0.4 37 1797 2.1
Female 1948 95007 2.1 344 90602 0.4 4881 249404 2.0
NA 29 0 0 0 3 0
Age (years)
0–4 0 3 0 7 0 1
5–9 0 1 0 3 0 0
10–14 4 21 0 8 1 1
15–19 9 79 4 26 15 14
20–24 15 249 3 37 17 125
25–29 16 374 5 94 40 874 4.6
30–34 28 670 4.2 10 238 82 3317 2.5
35–39 48 1447 3.3 14 614 191 8398 2.3
40–44 80 2842 2.8 27 1722 1.6 290 15257 1.9
45–49 117 4949 2.4 43 3992 1.1 416 20787 2.0
50–54 172 8770 2.0 43 8660 0.5 509 29098 1.7
55–59 302 15613 1.9 111 16463 0.7 587 31710 1.9
60–64 398 20368 2.0 119 23762 0.5 625 30317 2.1
65–69 512 26795 1.9 117 30799 0.4 583 27210 2.1
70–74 643 32600 2.0 153 38454 0.4 484 22559 2.1
75–79 698 35483 2.0 111 41973 0.3 502 22167 2.3
80–84 553 30667 1.8 33 31891 0.1 332 19093 1.7
85+ 387 25863 1.5 7 20740 0.0 234 20273 1.2
NA 45 0 2 0 13 0
Year
2001 751 28329 2.7 139 31141 0.4 865 34352 2.5
2002 705 28410 2.5 122 30512 0.4 867 34223 2.5
2003 546 28787 1.9 101 30757 0.3 637 36261 1.8
2004 535 29575 1.8 95 31161 0.3 654 36182 1.8
2005 435 30167 1.4 107 31684 0.3 567 36990 1.5
2006 513 30627 1.7 120 32425 0.4 650 36803 1.8
2007 542 30899 1.8 118 31803 0.4 681 36390 1.9
Registry
Eastern Cancer Registration & Information Centre (ECRIC) 527 23232 2.3 106 21396 0.5 722 28501 2.5
North west Cancer Intelligence Service 533 27881 1.9 111 35384 0.3 562 32831 1.7
Northern & Yorkshire Cancer Registry & Information Service 317 29769 1.1 85 37541 0.2 325 32904 1.0
Oxford Cancer Intelligence Unit 134 10220 1.3 54 9081 0.6 185 13835 1.3
South west Cancer Intelligence Service 290 32726 0.9 87 27780 0.3 298 39368 0.8
Thames Cancer Registry 1639 39740 4.1 204 42236 0.5 2224 51915 4.3
Trent Cancer Registry 165 20448 0.8 43 23310 0.2 214 24693 0.9
West Midlands Cancer Intelligence Unit 359 22778 1.6 105 22755 0.5 355 27154 1.3
NA 63 0 7 0 36 0
Abbreviations: HESO¼Hospital Episode Statistics (HES)-only records from the linked repository (version 2007) with a surgery code for ‘major surgery’; H/R¼HESO/REPO
expressed as a percentage, computed for numerators 420 cases; NCIN¼National Cancer Intelligence Network; REPO¼valid cancer registrations from the linked repository.
(These exclude the HESO records). Analysis based on first occurrences of the particular type of cancer in a person. Major surgery is defined as in the forthcoming NCIN surgery
report. The definitions are available.
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(2001–2007), and cancer registry. We plotted the incompleteness
measure for each cancer registry for each year.
To evaluate the possible magnitude of survival time error, we
identified all cases in the cancer registry records with a recorded
survival time of o1 year. These rapidly fatal cases were considered
as the ones most likely to be influenced by a systematic survival
time error. Within the three groups of cancers, we searched the
HES records for evidence of an earlier cancer diagnosis for these
persons (with or without a record of surgery), and used the first
matching HES record with a relevant diagnosis code. We
computed the difference in survival time (days) using the two
alternative dates of diagnosis. We described the distributions
of the survival time difference, stratified by type of cancer, and
cancer registry.
Finally, we evaluated the likely magnitude of the influence of
incompleteness and survival time error on a commonly used
outcome measure: the 1-year survival proportion. We computed
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Figure 1 Percentage of HES-only cases in cancer registries in England, 2001–2007: (A) colorectal cancer, (B) lung cancer, and (C) breast cancer.
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registries, (ii) with account taken of the HES-only cases and their
respective 1-year survival, and (iii) with further account taken of
the extent of possible survival time error in the cancer registration
records.
RESULTS
Table 1 shows the estimated incompleteness of case ascertainment.
The HES-only cases added 1.9% to the number of colorectal cancer
registrations, 0.4% to lung cancer, and 2.0% to breast cancer.
These effects were similar in males and females, slightly higher in
the younger age groups, and declined over the period 2001–2007.
There was some variation between cancer registries, with the
highest incompleteness in the Thames Cancer Registry (4.1% in
colorectal cancer, 0.5% in lung cancer, and 4.3% in breast cancer)
and lowest in the Trent and the South West registries. There was a
general decrease in incompleteness over time in most cancer
registries (Figure 1). Table 2 and Figure 2 show the analysis of
survival time error. The distribution of the difference between the
two computed survival times (survival time according to HES data
(HES-derived) minus survival time according to the cancer registry
(registry-derived)) was extremely skewed. For colorectal cancer
and lung cancer, 5.1% and 4.7% (respectively) of cases had
a difference of 41 month, and 0.8% and 0.4% (respectively) had a
difference of 41 year. Figures 2A and B show that the registries
had similar cumulative distributions after about 3 months (i.e., the
proportions of registrations with a difference of 43 months were
similar across the registries). The North West cancer registry had
a higher proportion of cases with a survival time difference of 41
month.
For breast cancer, 6.2% of cases had a survival time difference
of more than 1 month and 2.7% differed by 41 year. There was
variation in the distributions between the cancer registries, which
persisted for 41 year (Figure 2C). The proportion of cases with
survival difference of 41 year ranged from 0.8% in Northern and
Yorkshire to 4.4% in Trent.
Table 3 shows the three alternative analyses of 1-year survival.
The 1-year survival estimates increased when the HES-only cases
and their respective survival times were considered in the analysis.
The changes were small, amounting to 0.5, 0.2, and 0.2 percentage
points for colorectal, lung, and breast cancer, respectively. With
the further use of the HES-derived survival times for the cancer
registration records, the 1-year survival times increased further but
the changes remained small: 1.0, 0.8, and 0.4 percentage points,
respectively.
DISCUSSION
The main findings from this analysis are that completeness of
case ascertainment in English cancer registries is high, possibly
as much as 98–99%, when evaluated against independently
recorded hospital episodes which included relevant cancer
diagnosis and surgery codes. The analysis found evidence of the
hypothesised survival time error. Around 5–6% of rapidly fatal
(1 year) cancer registrations had the survival time extended by
Table 2 Difference in survival time from date of diagnosis in cancer registration and from earliest episode in HES, England 2001–2007
Survival difference Proportion that changed (%)
Same
Within
1 month
Within
1 year Total No change
More than
1 month
More than
1 year
Colorectal cancer registry
Eastern Cancer Registration & Information Centre (ECRIC) 4207 7134 7390 7460 56.4 4.4 0.9
North West Cancer Intelligence Service 5362 8652 9643 9729 55.1 11.1 0.9
Northern & Yorkshire Cancer Registry & Information Service 6366 9581 9730 9750 65.3 1.7 0.2
Oxford Cancer Intelligence Unit 2041 3142 3235 3244 62.9 3.1 0.3
South West Cancer Intelligence Service 7431 10110 10459 10563 70.3 4.3 1.0
Thames Cancer Registry 8668 13075 13669 13859 62.5 5.7 1.4
Trent cancer registry 4799 6993 7221 7284 65.9 4.0 0.9
West Midlands Cancer Intelligence Unit 4448 7374 7711 7756 57.3 4.9 0.6
Total 43322 66061 69058 69645 62.2 5.1 0.8
Lung cancer registry
Eastern Cancer Registration & Information Centre (ECRIC) 10627 15534 16004 16045 66.2 3.2 0.3
North West Cancer Intelligence Service 17740 23860 26910 27094 65.5 11.9 0.7
Northern & Yorkshire Cancer Registry & Information Service 20316 27565 27956 27996 72.6 1.5 0.1
Oxford Cancer Intelligence Unit 5008 6769 6920 6931 72.3 2.3 0.2
South West Cancer Intelligence Service 15843 20318 20978 21079 75.2 3.6 0.5
Thames Cancer Registry 22258 30237 31365 31536 70.6 4.1 0.5
Trent Cancer Registry 13096 17106 17554 17634 74.3 3.0 0.5
West Midlands Cancer Intelligence Unit 11193 16652 17430 17484 64.0 4.8 0.3
Total 116081 158041 165117 165799 70.0 4.7 0.4
Breast cancer registry
Eastern Cancer Registration & Information Centre (ECRIC) 1801 2183 2238 2287 78.7 4.5 2.1
North West Cancer Intelligence Service 2113 2847 3037 3141 67.3 9.4 3.3
Northern & Yorkshire Cancer Registry & Information Service 2002 2422 2462 2481 80.7 2.4 0.8
Oxford Cancer Intelligence Unit 900 1020 1030 1040 86.5 1.9 1.0
South West Cancer Intelligence Service 3194 3592 3719 3821 83.6 6.0 2.7
Thames Cancer Registry 3684 4383 4588 4768 77.3 8.1 3.8
Trent Cancer Registry 2112 2472 2569 2687 78.6 8.0 4.4
West Midlands Cancer Intelligence Unit 1838 2250 2313 2347 78.3 4.1 1.4
Total 17644 21169 21956 22572 78.2 6.2 2.7
All cases died within 1 year from diagnosis according to the cancer registry record.
Accuracy of cancer registry survival estimates
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records were extended by more than a year. However, the resulting
impact on estimates of 1-year survival was small, up to one
percentage point for colorectal cancer. There was some variation
in completeness and survival time difference between cancer
registries.
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Figure 2 Cumulative distributions of difference in survival time according to cancer registration and HES records, England, 2001–2007: (A) colorectal
cancer, (B) lung cancer, and (C) breast cancer.
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propose that it gives a full and accurate estimation of completeness
and survival time errors. The analysis uses a new source of data
and a pre-specified analysis plan to indicate the possible
magnitude and impact of the errors and biases proposed by Beral
and Peto (2010) and previously investigated and discussed
by ourselves (Bullard et al, 2000; Robinson et al, 2007; Møller
et al, 2009, 2010). We decided a priori to consider only resected
cases from HES as potentially missed cases in cancer registration,
these would be representatives of the non-fatal cancers that the
registration process might have missed (Bullard et al, 2000). The
most likely reason for any absence of surgical treatment of
hospitalised cancer patients would be that they were too ill to
be considered eligible for surgery. The exclusion of such patients
as potential cases is not likely to result in artificial underestimation
of survival, but rather the contrary.
A small proportion of cancer patients may have had their
diagnosis and surgery services provided in private hospitals,
particularly patients residing in the London area. Such patients are
not all recorded in the cancer registries and treatment services
provided on a private basis are not recorded in HES.
The analysis suggests a slightly lower completeness in the
youngest age groups, that is, colorectal and lung cancer patients
below 50 years and breast cancer patients below 35 years (Table 1).
This observation is based on small numbers. The good prognosis
of young patients may be a contributing factor to this.
The principal limitation of the study lies in the completeness of
the record linkage with the HES data and the accuracy of the
information therein. Unique person identifiers (NHS numbers)
have come to be almost universally used in NHS hospitals only
in the last few years, and this puts a limit on the period covered
in the linked data set. The year-on-year improvement in the
availability of NHS numbers and in the completeness of the record
linkage is the most likely reason for the slightly lower estimated
completeness in 2001 and 2002 for colorectal cancer and breast
cancer (Table 1).
Even in the most recent period, the linkage algorithm used NHS
number, sex, date of birth, postcode, and date of death, and it is
known to be imperfect. Some of the apparent HES-only cases
will in fact have a corresponding record in the cancer registry, and
there may be duplication whereby more than one of the HES-only
cases relates to a single person.
Additionally, there are known errors in the routine HES data
(as in any administrative data set) and some cases will have been
missed because they did not include the specific cancer diagnosis
or a relevant surgery code. We are not able to determine the
direction and magnitude of errors created by these imperfections,
but it seems unlikely that our analysis is severely flawed or biased.
We will continue to explore means of quality assurance and
improvement of the cancer registry records. The new linked data
set will gradually improve through quality assurance processes
related to the continuous use of the data and its annual updating.
Taken at face value, the 1–4% incompleteness in the Thames
Cancer Registry is about as we would expect from previous
analyses (Bullard et al, 2000; Robinson et al, 2007) and a recent
update thereof (unpublished data, available on request). It is
reassuring that most registries seem to have even higher complete-
ness than Thames. The analysis of survival time differences
between HES and cancer registries serves as a sensitivity analysis
of survival estimates derived from English cancer registry data,
but it should not be inferred that the earlier diagnosis date from
HES is the correct one, particularly when the difference is small.
The date of diagnosis concept in cancer registration does not
always take the date of first hospital activity or first clinical
diagnosis. In many cases, the date (often later) of the definitive
histopathological diagnosis will prevail, in accordance with the
international definition of date of diagnosis. The observed distri-
bution of survival time differences in the North West cancer
registry could be due to a more rigorous application of this rule,
and does not necessarily point to a particular problem in the
processing of death certificate information. The differences we
have found between cancer registries will be explored by the
registries and used in their continued quality assurance and
improvement of the service.
In conclusion, we confirm the hypothesis (Beral and Peto,
2010) – and our own expectations (Bullard et al, 2000; Robinson
et al, 2007; Møller et al, 2010) – that incompleteness of case
ascertainment and survival time error are real phenomena which
bias cancer survival estimates in the direction of too low estimates.
The error is very small compared with the observed differences
between North West European countries (Møller et al, 2009,
2010) and between socioeconomic groups in England (Møller et al,
personal communication). Although the British situation, with
immediate availability and processing of information from death
certificates, entails a risk of dependence on this source of
information, this is more desirable than the situation in several
other European countries where death information can only be
processed with technical difficulty and delay, or where it is
considered as sensitive and not available for cancer registration
(Møller et al, 2009). The estimates of completeness in cancer
registries in England are generally consistent with estimates from
other national cancer registries that process information from
death certificates in the primary case ascertainment, for example,
Finland (Robinson et al, 2007) and Norway (Larsen et al, 2009).
In the mid-1990s, the Thames Cancer Registry had 15–20%
registrations based entirely on death certificates, and the data
would not at present be considered as suitable for cancer
survival analysis. This death certificate-only proportion has been
Table 3 Case numbers and deaths within 1 year according to cancer registry data and HES data, and impact on one-year survival estimates, England,
2001–2007
Case numbers One-year survival estimate (%)
Cancer group
Registry
cases
diagnosed
2001–2007
HES-only
cases
diagnosed
2001–2007
Registry
cases died
within
365 days
HES-only
cases died
within
365 days
Registry cases died
within 365 days
using revised
diagnosis date
According
to registry
records
According
to registry
and HES-only
records
According to registry
(using revised
diagnosis date)
and HES-only records
A B C D E (1) (2) (3)
Colorectal cancer 206794 4027 69645 353 68654 66.3 66.8 67.3
Lung cancer 219483 802 165799 46 164485 24.5 24.7 25.3
Breast cancer 251201 4921 22572 82 21858 91.0 91.2 91.4
Abbreviation: HES¼Hospital Episode Statistics. A: as reported in Table 1 on completeness of case ascertainment; B: as reported in Table 1 on completeness of case
ascertainment; C: these cases died within 1 year according to the cancer registry data; D: these HES-only cases died within 1 year according to the HES data; E: with date
of diagnosis revised, some registry cases now survive longer than 1 year. (1)¼(A–C)/A; (2)¼((A+B)–(C+D))/(A+B); (3)¼((A+B)–(E+D))/(A+B).
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can no longer be simply dismissed as unfit-for-purpose. It is worth
noting that the errors we have discussed are not specific to the
British situation but will exist in the same form or in similar forms
in other countries as well. The best strategy is to be careful in
the selection of comparison countries and to retain a critical (and
self-critical) attitude to the international cancer survival and
cancer mortality comparisons we perform (Holmberg et al, 2010;
Møller et al, 2010; Morris et al, 2011).
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